Gerresheimer shares down on outlook, but key contracts confirmed
Reuters
Published Apr 11, 2024 08:32
Updated Apr 11, 2024 16:45
By Louis van Boxel-Woolf
(Reuters) - The CEO of Germany's Gerresheimer confirmed on Thursday that the maker of packaging and medical equipment has contracts with leading players in the burgeoning weight-loss drugs sector, but its shares fell 4.4% after investors were underwhelmed by its second-quarter outlook.
Though the company reiterated its core profit (adjusted EBITDA) forecast of 430 million to 450 million euros ($461.52 million to $482.99 million) for the year, CEO Dietmar Siemssen told analysts on a conference call that the ongoing reduction of inventory would weigh on the primary packaging glass division for the near future.
"We are still facing an ongoing destocking situation in the market, mainly in the vial business," he said, adding that the effect was "gradually decreasing in the next few months and we expect a strong second-half 2024."
First-quarter earnings at Gerresheimer's primary packaging glass division, which makes the vials, fell 14.5% versus last year to reach 34.8 million euros. But earnings at its plastics and devices division, which makes syringes and injector pens, jumped 26.5% to 59.3 million euros.
"It seems some investors are disappointed with the growth outlook for Q2 as management reiterated its guidance for low single-digit organic revenue growth in H1, mainly due to the destocking of vials," said Berenberg analyst Victoria Lambert.
Siemssen also told investors on the call that Gerresheimer has contracts with "the only two key players" in the market for appetite-suppressing GLP-1 agonists, adding that "the sales that you see at the moment are a result of deliveries to these two customers."
Injectors of the kind made by Gerresheimer are used to administer Novo Nordisk (CSE:NOVOb)'s Wegovy and Eli Lilly (NYSE:LLY)'s Zepbound. The blockbuster GLP-1 agonists are expected to bring at least 350 million euros of annual revenue for Gerresheimer within three years, Siemssen said last month, without naming specific customers.
($1 = 0.9317 euro)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.